- Home
- NATR vs GOSS Comparison
NATR vs GOSS Comparison
Compare NATR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATR | GOSS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.1M | 796.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NATR | GOSS |
|---|---|---|
| Price | $21.50 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $21.33 | $8.60 |
| AVG Volume (30 Days) | 107.1K | ★ 4.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $474,542,000.00 | $44,051,000.00 |
| Revenue This Year | $7.30 | N/A |
| Revenue Next Year | $3.44 | $6.41 |
| P/E Ratio | $27.16 | ★ N/A |
| Revenue Growth | ★ 6.62 | N/A |
| 52 Week Low | $11.01 | $0.76 |
| 52 Week High | $24.12 | $3.87 |
Technical Indicators
Market Signals| Indicator | NATR | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 55.86 | 46.76 |
| Support Level | $21.42 | $3.21 |
| Resistance Level | $23.03 | $3.87 |
| Average True Range (ATR) | 0.82 | 0.29 |
| MACD | -0.25 | -0.06 |
| Stochastic Oscillator | 28.03 | 3.42 |
Price Performance
Historical ComparisonAbout NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.